HWHG(SH:600079) Cai Jing Wang·2025-11-21 14:11Core Viewpoint - Yichang Renfu Pharmaceutical, a subsidiary of Renfu Pharmaceutical (600079), has received approval from the National Medical Products Administration for the marketing authorization application of Dexmethylphenidate Hydrochloride Capsules, indicating a significant step in expanding its product portfolio in the ADHD treatment market [1] Group 1: Company Developments - Renfu Pharmaceutical holds an 80% stake in Yichang Renfu, which is actively pursuing the registration of Dexmethylphenidate Hydrochloride Capsules [1] - The company has invested approximately 90 million RMB in the research and development of this product [1] Group 2: Market Context - Dexmethylphenidate Hydrochloride Capsules are approved in the U.S. for treating Attention Deficit Hyperactivity Disorder (ADHD) in adults and children aged 6 and above, as well as moderate to severe Binge Eating Disorder (BED) [1] - Currently, there are no similar products approved for sale in China, indicating a potential market opportunity for Yichang Renfu [1]